CD4 and neoplasm: We found that the untreated tumor-bearing mice had a very low T cell population, 3-fold less than healthy naive mice, whereas the JOL2888 treatment elicited a T cell response, with 13% and 8% of CD4+ and CD8+ cells, respectively.